Skip to main content

The predictive utility of circulating PCSK9 levels on diabetes mellitus


Increasing data including ours have suggested that proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel regulator of cholesterol metabolism, may also play an important role in the development of type 2 diabetes mellitus (T2DM) and is associated with clinical outcomes in diabetic patients. Previous studies revealed that elevated plasma PCSK9 levels had a higher incidence of new-onset T2DM. Moreover, the results of available epidemiological, preclinical, and clinical studies have indicated that plasma PCSK9 concentration is correlated with glycemic parameters and can predict the adverse cardiovascular events in diabetic patients with coronary artery disease. However, there is currently no general agreement about the association of PCSK9 with T2DM. The usefulness of the circulating PCSK9 concentration as a predictor for the risk of new-onset T2DM should be clinically prudential.

We have read the article with great interest by Shi et al. on the relationship of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration with the risk of incident type 2 diabetes mellitus (T2DM) in prediabetic Chinese population [1]. They concluded that elevated PCSK9 levels were associated with an increased incidence of T2DM in female individuals with prediabetes (pre-DM).

In fact, the best-known function of PCSK9 is to take part in cholesterol metabolism by acting on low-density lipoprotein receptor expressed in the liver, resulting in a remark increase of circulating low-density lipoprotein cholesterol [2]. Additionally, circulating PCSK9 concentration has also been proposed to be a novel biomarker for predicting the coronary artery calcification, coronary severity and worse cardiovascular outcomes in different clinical settings including general population, subjects with stable coronary artery disease (CAD), patients with familial hypercholesterolemia, and individuals with arterial fibrillation [2]. Besides, the association between PCSK9 and T2DM has becoming an interesting issue since its discovery. It was previously showed that plasma PCSK9 levels were higher in patients with T2DM [3]. Moreover, the results available from epidemiology, preclinical and clinical studies suggested a positive correlation of circulating PCSK9 concentration with glycemic parameters and risks of T2DM [3]. Meanwhile, a recent animal study has revealed that downregulating PCSK9 can ameliorate lipid and glucose metabolism [4].

Clinically, pre-DM, the intermediate hyperglycemia, is a high-risk state for developing T2DM. Emerging data have already supported that disturbed glycemic metabolism plays a major role in atherosclerosis and cardiovascular diseases. Hence, it is critical to provide methods for identification of individuals at risk of pre-DM or T2DM on the basis of indices available to doctors [5]. Additionally, understanding the progression of pre-DM, identifying influencing factors for T2DM in a timely and accurate manner and making interventions to reduce the risk for T2DM are necessary among the patients with pre-DM. It has indicated that several factors are associated with the risks of T2DM among prediabetic subjects, such as ageing, body mass index, obesity, family history of T2DM, elevated glycemic parameters, fasting insulin, and albuminuria [5].

Interestingly, Shi et al. found a positive relationship with elevated baseline circulating PCSK9 levels and incidence of T2DM in female population with pre-DM during 3.1 years follow-up, which was the first study to undertake a longitudinal analysis of circulating PCSK9 concentration and the development of T2DM in prediabetic individuals [1]. Although their finding provided an additional information on the association with circulating PCSK9 concentration and the incident risk of new-onset T2DM, there were several issues might be worth deliberating before making a conclusion.

First of all, a gender imbalance of patients enrolled in this study might be a problem. Numerous studies have indicated that a gender difference can be found, which leads to different outcomes, for example, men have higher risks of CAD compared with women [6]. The current study also found a remark gender difference in the association of PCSK9 levels with incidence of T2DM in women but not men. As we have already known that men appeared to be at greater risk of T2DM at a younger age compared to women [7]. What’s more, in this study the percentage of females had an absolute advantage (67 %, n = 2817) than that of males (33.0 %, n = 1388), which might influence the results. If the numbers of males in the present study was analogous, the correlation of PCSK9 concentration might also be similar. Thereby, further investigation may be needed in young, well-gender balanced populations. Alternatively, an age- and sex-matched case–control study would be suggested.

Secondly, previous studies showed that circulating PCSK9 levels could be affected by multiple factors, including exercise, smoking, alcohol or tea consumption, and lipid-lowering drugs [8]. As shown by prior observations, several lipid-lowering medications could significantly up-regulate the expression of PCSK9 genes and increase circulating PCSK9 concentration even if a single dose of statin, ezetimibe, Xuezhikang, or berberine was administrated [8]. Notably, the duration of lipid-lowering drug treatment is also an important factor for affecting PCSK9 levels. In order to avoid this impact on the baseline levels of PCSK9, it is recommended to exclude patients who took any lipid-lowering drugs within 3 months before enrollment. In this article, authors did not provide detailed information regarding to tea consumption and the usage of lipid-lowering agents. In addition, for prediabetic patients, lifestyle intervention is the cornerstone of T2DM prevention, with evidence of a 40–70% relative-risk reduction during follow-up time [5]. Likewise, most guidelines have recommended the high-intensity life intervention on preferred T2DM prevention intervention [9]. Nevertheless, Shi et al. only recorded physical activity of each prediabetic individual at baseline but no information concerning their lifestyle intervention including diet and exercise during the follow-up time. Despite the sample size of the current study was relatively large, the lack of these important baseline and follow-up information might weaken the conclusion on the relationship of PCSK9 with incidence of T2DM. A prospective, randomized case–control study may be needed to make sure that PCSK9 is associated with increased risk of new-onset T2DM in patients with pre-DM.

Thirdly, it is also worth noting that the individuals with pre-DM is considered to have higher risk of developing T2DM compared to subjects with normal glucose regulation (NGR) [5]. Furthermore, in analysis of our data published recently [3], all 1225 patients with stable CAD were further divided into three subgroups according to diabetic status (T2DM: n = 377, pre-DM: n = 489, NGR: n = 359) and an ascending increment of baseline levels of PCSK9 were observed [T2DM vs. pre-DM vs. NGR: 246.51 (199.43, 292.22) vs. 238.88 (198.53, 275.65) vs. 225.31 (185.95, 263.36) ng/mL, Fig. 1]. Hence, it might be much better that a subgroup of NGR was covered in their study to examine the relation of circulating PCSK9 concentration with future diabetic incidence. Generally, the predictive utility of circulating PCSK9 levels on T2DM need to be further confirmed.

Fig. 1

Circulating PCSK9 levels according to diabetic status. PCSK9 proprotein convertase subtilisin/kexin type 9, NGR normal glucose regulation, Pre-DM prediabetes, T2DM type 2 diabetes mellitus. # p < 0.01

Availability of data and materials

Not applicable.



Proprotein convertase subtilisin/kexin type 9


Type 2 diabetes mellitus




Coronary artery disease 


Normal glucose regulation


  1. 1.

    Shi J, Zhang W, Niu Y, Lin N, Li X, Zhang H, Hu R, Ning G, Fan J, Qin L, et al. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study. Cardiovasc Diabetol. 2020;19(1):209.

    CAS  Article  Google Scholar 

  2. 2.

    Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022–36.

    CAS  Article  Google Scholar 

  3. 3.

    Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX, et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):167.

    CAS  Article  Google Scholar 

  4. 4.

    Wang Y, Ye J, Li J, Chen C, Huang J, Liu P, Huang H. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Cardiovasc Diabetol. 2016;15:19.

    CAS  Article  Google Scholar 

  5. 5.

    Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90.

    Article  Google Scholar 

  6. 6.

    Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev. 2017;97(1):1–37.

    Article  Google Scholar 

  7. 7.

    Kautzky-Willer A, Harreiter J, Abrahamian H, Weitgasser R, Fasching P, Hoppichler F, Lechleitner M. [Sex and gender-specific aspects in prediabetes and diabetes mellitus-clinical recommendations (Update 2019)]. Wien Klin Wochenschr. 2019;131(Suppl 1):221–8.

    Article  Google Scholar 

  8. 8.

    Cui CJ, Li S, Li JJ. PCSK9 and its modulation. Clin Chim Acta. 2015;440:79–86.

    CAS  Article  Google Scholar 

  9. 9.

    Carris NW, Magness RR, Labovitz AJ. Prevention of diabetes mellitus in patients with prediabetes. Am J Cardiol. 2019;123(3):507–12.

    Article  Google Scholar 

Download references


Not applicable.


This study was partly supported by Capital Health Development Fund (201614035), Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-I2M-1-011), and Chinese Cardiovascular Association-V.G fund (2017-CCA-VG-017).

Author information




PJ wrote the draft of the article, which was critically guided by ZCG and LJJ. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jian-Jun Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peng, J., Zhu, CG. & Li, JJ. The predictive utility of circulating PCSK9 levels on diabetes mellitus. Cardiovasc Diabetol 20, 45 (2021).

Download citation


  • Proprotein convertase subtilisin/kexin type 9
  • Type 2 diabetes mellitus
  • Risks